DOJ Charges Glenmark With Generic Drug Price-Fixing
By Bryan Koenig (June 30, 2020, 9:50 PM EDT) -- The U.S. Department of Justice announced new criminal charges late Tuesday in its investigation of price-fixing in the generic-drug industry, this time accusing Glenmark Pharmaceuticals Inc. USA in Pennsylvania federal court of overcharging by at least $200 million for a cholesterol treatment.
Glenmark is the fifth company charged so far in the DOJ's generic-drug probe, which has paralleled massive multidistrict litigation from state attorneys general and private parties against most of the generic-drug industry. The charges against Glenmark take the form of a criminal information rather than an indictment.
According to the DOJ, Glenmark conspired with one of the companies already...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!